What is the appropriate workup for thrombocytopenia and when are corticosteroids beneficial versus ineffective?

Workup for Thrombocytopenia

For initial thrombocytopenia workup, test for HCV and HIV, evaluate the blood smear for abnormalities beyond isolated thrombocytopenia, and skip bone marrow biopsy in patients with typical ITP presentation 1.

Essential Initial Testing

The 2019 ASH guidelines provide clear direction on what testing is mandatory versus optional:

Mandatory tests:

• HCV and HIV serology (strong recommendation) 1
• Complete blood count with peripheral smear review

Conditional additional workup:

• Pursue further investigations only if you find abnormalities beyond isolated thrombocytopenia on the blood count or smear (such as leukopenia, anemia not explained by iron deficiency, or atypical cells) 1
• Bone marrow examination is NOT necessary regardless of patient age if the presentation is typical for ITP 1

For secondary causes:

• Test for H. pylori (urea breath test, stool antigen, or endoscopic biopsy) and treat if positive 1
• Consider these tests when clinical context suggests secondary ITP

---

When Corticosteroids Help vs. When They Don't

When Corticosteroids ARE Effective

Corticosteroids are highly effective as first-line therapy for primary ITP, achieving complete response in 74% and partial response in 18% of patients, with median time to response of 15 days 2.

Primary ITP (Immune Thrombocytopenia)

• Initial treatment of choice for primary ITP 1, 3
• Response rates: 92.4% overall response (74.2% complete response, 18.2% partial response) 2
• However, only 50% achieve sustained remission after stopping steroids 2
• The 2026 ASH guidelines now suggest combining rituximab or thrombopoietin receptor agonists with corticosteroids for initial therapy rather than corticosteroids alone 4

Pregnancy-Related ITP

• Corticosteroids or IVIG are recommended for pregnant patients requiring treatment 1

HIV-Associated ITP

• Use corticosteroids, IVIG, or anti-D as initial ITP treatment if antiretroviral therapy alone is insufficient 1

Specific Dosing Considerations

• Predniso(lo)ne is standard, but dexamethasone is an alternative when rapid platelet increase is needed 5
• Limit duration of corticosteroid use - modern guidelines emphasize shorter courses 3, 6

---

When Corticosteroids Are NOT Effective or Should Be Avoided

Drug-Induced Thrombocytopenia

Corticosteroids show NO therapeutic benefit in drug-induced thrombocytopenia - recovery occurs at the same rate with or without steroids (median 8 days) 7. The key intervention is stopping the offending drug. Despite this, corticosteroids are still recommended for severe symptomatic cases because initial differentiation from ITP is difficult 7.

HCV-Associated ITP

• Antiviral therapy should be considered first 1
• If ITP treatment is needed, use IVIG rather than corticosteroids as initial therapy 1
• Monitor closely as interferon can worsen thrombocytopenia 1

HIV-Associated ITP

• Antiretroviral therapy should be prioritized before other treatments unless clinically significant bleeding is present 1

Corticosteroid-Resistant or Relapsed ITP

• Approximately 25-50% of patients don't achieve sustained remission with corticosteroids 2, 8
• For these patients, second-line options include:
  • Thrombopoietin receptor agonists (strong recommendation) 4
  • Rituximab (conditional recommendation) 4
  • Fostamatinib 3
  • Splenectomy 1

---

Important Caveats and Clinical Pitfalls

Duration of Steroid Use

• 23% of patients continue corticosteroids at 24 weeks, which is excessive 6
• Modern practice trends toward shorter courses - median duration decreased from historical norms to 41 days in recent Japanese data 6
• Long-term use (≥10 mg/day at 12 weeks) occurred in 12% of patients and is associated with significant adverse outcomes 6

Adverse Effects

• New-onset hypertension and/or diabetes mellitus develops in 10.6% of ITP patients on corticosteroids 2
• Risk of adverse outcomes is significantly associated with corticosteroid use 6
• Patients with pre-existing diabetes, hypertension, or cardiovascular disease are at higher risk

Modern Treatment Paradigm Shift

• The 2026 ASH guidelines represent a major shift: combination therapy (rituximab + corticosteroids OR thrombopoietin agonist + corticosteroids) is now preferred over corticosteroids alone for initial therapy 4
• Thrombopoietin receptor agonist prescriptions exceeded corticosteroid prescriptions in Japan by 2021 6
• Treatment should be based on patient needs rather than disease stage, with quality of life considerations 3